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Abstract: WIN55,212-2 (WIN) is a synthetic agonist of cannabinoid receptors that displays promising
antitumour properties. The aim of this study is to demonstrate that WIN is able to block the migratory
ability of osteosarcoma cells and characterize the mechanisms involved. Using wound healing
assay and zymography, we showed that WIN affects cell migration and reduces the activity of the
metalloproteases MMP2 and MMP9. This effect seemed to be independent of secreted protein acidic
and rich in cysteine (SPARC), a matricellular protein involved in tissue remodeling and extracellular
matrix deposition. SPARC release was indeed prevented by WIN, and SPARC silencing by RNA
interference did not influence the effect of the cannabinoid on cell migration. WIN also increased
the release of extracellular vesicles and dramatically upregulated miR-29b1, a key miRNA that
modulates cell proliferation and migration. Interestingly, reduced cell migration was observed in
stably miR-29b1-transfected cells, similarly to WIN-treated cells. Finally, we show the absence of
SPARC in the extracellular vesicles released by osteosarcoma cells and no changes in SPARC level
in miR-29b1 overexpressing cells. Overall, these findings suggest that WIN markedly affects cell
migration, dependently on miR-29b1 and independently of SPARC, and can thus be considered as a
potential innovative therapeutic agent in the treatment of osteosarcoma.
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1. Introduction
Osteosarcoma (OS) is a primary malignant bone tumour that most often affects males with two
incidence peaks, one of which is between 10 and 40 years of age and the other in the elderly [1,2].
In particular, the marked osteoblastic and osteogenic activity of adolescent age seems to be a
predisposing factor for the onset of the neoplasia [3]. The first indication of the use of chemotherapy
in patients with OS dates back to 30 years ago, and there is currently a full consensus in considering
the combination of surgery and chemotherapy as a standard procedure in treating high-grade OS.
However, although the tumour can respond to chemotherapy treatment, in patients with metastatic
disease, the prognosis remains adverse [4]. Thus, a better understanding of osteosarcoma biology
represents an important challenge for researchers to optimize treatment strategies and develop new
therapeutic agents, thus improving the prognosis.
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Cannabinoids (CBs), the active constituents of Cannabis sativa, are known to exert a wide range
of neuronal central and peripheral effects. Recently, a role of cannabinoids in the regulation of cell
death and survival has largely emerged [5–7]. In particular, numerous studies have explored the
anti-proliferative effects of these compounds in various tumours [8]. Following the interaction with
their specific receptors, cannabinoids can trigger several different signalling pathways [9], including the
accumulation of ceramide, the activation of c-Jun N-terminal kinase (JNK) and p38 MAPK, as well as
the increase in calcium concentration, reactive oxygen species (ROS) production and the modulation of
pro- and anti-apoptotic members of the Bcl-2 family [10–13]. More recently, a relationship between the
cannabinoid system and miRNA expression has been evidenced. MiR-Let-7d has been demonstrated
to be a target of cannabinoid receptors [14], and the anticancer activity of WIN was related to the
miR-27a-mediated repression of specificity protein (Sp) transcription factor in colon cancer cells [15].
In recent years, oncology research has investigated specific aspects of the cellular processes involved
in cell death caused by synthetic cannabinoid derivatives with anticancer activity. Our previous
studies have shown the in vitro effects of the synthetic cannabinoid WIN55,212-2 on different cancer
cell lines [16–18]. In particular, we showed that treatment with increasing doses of WIN induces
a significant reduction of the proliferative ability of MG63 osteosarcoma cells and sensitizes them
to apoptosis induced by TRAIL, a cytokine with selective anticancer activity [19]. The analysis of
biochemical pathways evidenced an important role played by the WIN-dependent increase in the
control of the intracellular level of SPARC (secreted protein acidic and rich in cysteine), a multi-faceted
glycoprotein which is involved in a number of cellular processes [20,21].
In addition to pro-apoptotic and anti-proliferative roles, other studies reported that synthetic
cannabinoids can also reduce the migration, angiogenesis, invasion and metastasis of cancer cells by
modulating the levels of proteins involved in these processes [22]. On the other hand, it is well known
that SPARC participates in the regulation of cell adhesion, migration, and tissue remodelling [23].
In particular, it has been shown that low expression levels of matricellular SPARC can modulate cell
migration in different types of cancer cells, and these observations led researchers to hypothesize a
specific role of SPARC in the inhibition of tumour progression and invasiveness. In contrast, many
other studies demonstrated an oncogenic function of SPARC, thereby highlighting the divergent roles
of SPARC in human carcinogenesis [24].
Other interesting players in the regulation of cell migration in different types of cancer cells
are the members of the miR-29 family, including products from two gene loci: miR-29a/b1, located
on chromosome 7 (7q 32.2); and miR-29b2/c, located on chromosome 1 (1q 32.2) [25]. It has been
demonstrated that the forced overexpression of miR-29 is able to inhibit cell migration and proliferation
and promote the apoptosis of tumour cells, while its reduced levels are a frequent occurrence in
osteosarcoma tissues [26,27]. However, although it is known that miR-29 is a regulator of SPARC
expression [28], the exact correlation between these two players in cannabinoid action is a subject
of investigation.
The aim of the present study was to evaluate the effects of the cannabinoid WIN in osteosarcoma
MG63 cell migration and the possible involvement of SPARC and miR-29b1 in this event. Collectively,
our results show for the first time that WIN is able to inhibit osteosarcoma cell migration in a
SPARC-independent manner. Moreover, a crucial role seems to be played by the WIN-mediated
induction of miR-29b1. Therefore, the cannabinoid has the potential to be an efficient anti-cancer drug
in new therapeutic strategies for osteosarcoma.
2. Results
2.1. WIN Treatment Reduces the Migratory Ability of MG63 Cells and Affects MMP Activity
In a previous paper, we demonstrated the ability of WIN—a synthetic agonist of cannabinoid
receptors—to induce a significant reduction of osteosarcoma cell proliferation, and we characterized
the biochemical mechanisms involved [19]. Here, we aim to evaluate whether WIN can also induce a
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modification in the migratory ability of osteosarcoma MG63 cells. To this end, a monolayer of cells was
scraped longitudinally, and the rate of the re-population of the area between the wound edges after the
lesion was evaluated. Untreated MG63 cells showed a rapid healing process of the lesion, reaching
almost full monolayer repair at 48 h (T48) after scratching (not shown). As shown in Figure 1A, 5 µM
WIN markedly prevented cell migration, as indicated by the entity of the wound that was almost
identical to T0 at all time points observed. In contrast, untreated MG63 cells migrated in the gap,
reaching about 75% of migratory activity after 36 h (T36).
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Figure 1. WIN55,212-2 (WIN) treatment inhibits MG63 cell migration. The effect of WIN on MG63
wound healing in the absence (A) or presence of conditioned medium (B). After mechanical wounding,
confluent cells were treated with 5 µM WIN and cell migration was monitored over time. In (B),
before treatment, cell culture medium was replaced with conditioned medium from high confluence
cultures. Representative microphotographs were taken at the indicated time points after wounding
(magnification 200×). The average distances between cells at the edges of the gaps in the wound healing
assay were estimated by ImageJ software. Histograms reporting the mean percentage area healed at
T8, T24 and T36 post-wounding are shown on the right panels. (*) p < 0.05 and (**) p < 0.01 versus
untreated cells at the same time point.
In other experiments, before WIN treatment, we added a conditioned medium from a highly
confluent untreated cell culture to the cultured cells. As shown in Figure 1B, the presence of conditioned
medium accelerated the wound closure of untreated cell cultures, almost achieving total confluence at
T36, and partially prevented the anti-migratory effect induced by WIN. These data suggest that the
cells produce factors to sustain cell migration and that WIN treatment blocks their extracellular release
or reduces their action.
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Next, we analysed the levels and the activity of metalloproteinases (MMPs), a family of enzymes
which are responsible for normal tissue remodelling and angiogenesis. Gelatin zymography assay
showed that 5 µM WIN significantly reduced extracellular MMP9 and MMP2 gelatinolytic activity after
36 h of treatment, thus indicating that WIN inhibits metalloproteinase activity (Figure 2A). In addition,
Western blot analysis revealed that WIN was capable of inducing a dramatic decrease in the level of
intracellular MMP9 and a slight decrease in the level of MMP2 (Figure 2B).
Int. J. Mol. Sci. 2019, 20, x 4 of 15 
 
Next, we analysed t e le els and the activity of metall proteinases (MMPs), a family of 
enzymes which are respo sible for nor al tissue remodelling and angiogenesis. Gelatin 
zym graphy assay showed that 5 µM WIN significantly reduced extracellular MMP9 and MMP2 
gelatin lytic activity after 36 h of treatment, thus indicating that WIN inhibits metalloproteinase 
activity (Figure 2A). In addition, Western blot analysis revealed that WIN was capable of inducing a 
dramatic decrease in the level of intracellular MMP9 and a slight decrease in the level of MMP2 
(Figure 2B). 
 
Figure 2. WIN treatment inhibits metalloprotease activities. Gelatin zymography (A) and Western 
blotting analysis (B) of the metalloproteinases MMP2 and MMP9 in MG63 cells treated for 36 h with 5 
µM WIN. Arrows indicate the relative bands at 72 kDa (MMP2) and 92 kDa (MMP9). Blots are 
representative of three independent experiments with similar results. Densitometric analysis is 
reported in the histograms. (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 compared to the untreated 
sample. In (A), volumes containing equal amount of proteins were loaded, in (B), densitometric 
measurements were made after normalization with β-actin. 
2.2. WIN Treatment Prevents SPARC Release in the Extracellular Environment and Increases the Release of 
Extracellular Vesicles 
Among the numerous players implicated in regulating tumour cell migration and invasiveness, 
we specifically focused on SPARC protein and miR-29b1. The matricellular factor SPARC plays 
different roles in extracellular processes, and its function is strictly related to the cancer model 
and/or the metastatic grade of the tumour [29]. Since we previously demonstrated that, in 
osteosarcoma cells, the cytotoxic effect of WIN was accompanied by an increase in the level of 
SPARC [20], here, we aim to analyse a possible role of this factor in the anti-migratory effect of WIN 
in MG63 cells. To this end, we first analysed the level of SPARC in conditioned media collected from 
untreated or WIN-treated cells after dialysis and lyophilization. Although we have previously 
demonstrated that intracellular levels of SPARC increase under treatment with WIN [20], Western 
blotting analysis evidenced that the level of released SPARC was much more abundant in the 
medium from untreated cells compared to that obtained from WIN-treated cells (Figure 3A). 
In light of this observation, we wondered whether SPARC release was associated with 
extracellular vesicles (EVs). Therefore, we isolated EVs from the culture supernatants of untreated or 
WIN-treated MG63 cells by ultracentrifugation and quantified EVs obtained by both cytofluorimetry 
and acetylcholine esterase activity measurement (AChEase). As shown in Figure 3B, WIN induced a 
considerable increase in the amount of released EVs, which resulted to be about seven-fold higher 
Figure 2. WIN treatment inhibits metalloprotease activities. Gelatin zymography (A) and Western
blotting analysis (B) of the metalloproteinases MMP2 and MMP9 in MG63 cells treated for 36 h with
5 µM WIN. Arrows indicate the relative bands at 72 kDa (MMP2) and 92 kDa (MMP9). Blots are
representative of three independent experiments with similar results. Densitometric analysis is reported
in the histograms. (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 compared to the untreated sample. In (A),
volumes containing equal amount of proteins were loaded, in (B), densitometric measurements were
made after normalization with β-actin.
2.2. WIN Treatment Prevents SPARC Release in the Extracellular Environment and Increases the Release of
Extracellular Vesicles
Among the numerous players implicated in regulating tumour cell migration and invasiveness,
we specifically focused on SPARC protein and miR-29b1. The atricellular factor SPARC plays different
roles in extracellular processes, and its function is strictly related to the cancer model and/or the
metastatic grade of the tumour [29]. Since we previously demonstrated that, in osteosarcoma cells, the
cytotoxic effect of WIN was accompanied by an increase in the level of SPARC [20], here, we aim to
analyse a possible role of this factor in the anti-migratory effect of WIN in MG63 cells. To this end, we
first analysed the level of SPARC in conditioned media collected from untreated or WIN-treated cells
after dialysis and lyophilization. Although we have previously demonstrated that intracellular levels
of SPARC increase under treatment with WIN [20], Western blotting analysis evidenced that the level
of released SPARC was much more abundant in the medium from untreated cells compared to that
obtained from WIN-treated cells (Figure 3A).
In light of this observation, we wondered whether SPARC release was associated with extracellular
vesicles (EVs). Therefore, we isolated EVs from the culture supernatants of untreated or WIN-treated
MG63 cells by ultracentrifugation and quantified EVs obtained by both cytofluorimetry and
acetylcholine esterase activity measurement (AChEase). As shown in Figure 3B, WIN induced
a considerable increase in the amount of released EVs, which resulted to be about seven-fold higher
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than EVs isolated from untreated cell media. This result was confirmed by the consistent increase in
AChEase activity (Figure 3C).
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Figure 3. WIN treatment blocks secreted protein acidic and rich in cysteine (SPARC) release and
increases the number of extracellular vesicles. (A) Western blotting analysis of SPARC in media
derived from untreated or WIN-treated cells for 36 h. The media were dialyzed, concentrated by
lyophilization, and reconstituted with water. Protein samples were separated under reducing conditions,
and immunoblotting was performed using SPARC antibody. Red Ponceau staining was reported as
loading control. The results are representative of three independent experiments and densitometric
analysis is reported in the histograms. (***) p < 0.001 compared to untreated cells. (B) Flow cytometry
analysis of isolated extracellular vesicles (EVs) derived from untreated or WIN-treated MG63 cells.
Data are representative of three independent experiments. SSC, side scatter; FSC, forward scatter.
(C) Acetylcholine esterase (AChEase) activity in EVs from untreated or WIN-treated cells assessed
as reported in Section 4 and relative quantification. (D,E) Western blotting analysis of SPARC in
MG63 cell-derived EVs. Media from untreated or WIN-treated cells were collected and EVs isolated as
reported in Section 4. The immunoblotting of isolated EVs (D) or EV supernatants (E) was performed
to detect SPARC level. AchE activity (D) and Ponceau red staining (E) were used as loading control.
Representative blots of three independent experiments and densitometry analysis histograms are
depicted. (**) p < 0.01 compared to the untreated sample.
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Subsequently, we evaluated SPARC levels in EVs by Western blotting analysis. The results showed
a not significant level of SPARC in the vesicles, although the protein was present in the relative
supernatants from untreated cell cultures (Figure 3D,E).
Therefore, considering that SPARC is poorly represented in EVs, we evaluated whether this
protein can be secreted by MG63 cells via the canonic secretory pathway. For this purpose, we used
thapsigargin and BAPTA-AM, two specific inhibitors of this pathway. As shown in Figure 4, the level
of SPARC was significantly reduced in the medium from thapsigargin or BAPTA-AM-treated cells.
Accordingly, in the presence of secretory pathway inhibitors, the intracellular levels of SPARC were
higher than in control cells (Figure 4). Thus, we concluded that WIN could restrain SPARC inside the
cell by inhibiting the secretory pathway and that the effect of WIN on cell migration is independent of
the presence of SPARC in the extracellular compartment.
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Figure 4. Effects of secretory pathway inhibitors on SPARC levels. Western blotting analysis of
extracellular or intracellular level of SPARC after treatment with 5 µM WIN, 1 µM thapsigargin (THG)
or 5 µM BAPTA-AM (BAPTA). Ponceau red staining or β-actin blot were reported as loading control
for extracellular or intracellular protein levels, respectively. Representative blots of three independent
experiments and densitometry analysis histograms are depicted. (*) p < 0.05, (**) p < 0.01 compared to
the untreated sample. N.S. not sig ificant.
2.3. Silencing SPARC did not Affect the Anti-Migratory Effect of WIN
To validate the hypothesis that SPARC is not involved in the WIN-mediated anti-migratory effect,
we silenced SPARC expression by RNA interference. Figure 5A shows that SPARC was downregulated
in silenced cells at both the intracellular and extracellular level in the presence or absence of WIN.
The a alysis of cell migration in SPARC-silenced cells was then evaluated. The results reported in
Figure 5B show that—also in this case—WIN almost completely prevented the closure of the wound
after 36 h in both control (siScr-transfected) and siSPARC-transfected cells. In the absence of the
cannabinoid, transfected cells closed the gap with a migratory activity of about 80% regardless of the
level of SPARC.
Considering the substantial increase in the amount of released EVs after WIN treatment, we
evaluated whether EVs play a role i the control of cell migration. For this purpose, MG63 cells were
incubated in t e presence of the EVs isolated from conditioned medium of WIN-treated cell cultures.
As shown in Figure 6, EVs isolated from WIN-treated cells halted the wound closure similarly to
that observed after WIN treatment, whereas EVs isolate from untreated cult res did not induce any
modification in cell migration (not shown).
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SPARC siRNA (siSPARC) on the protein l vel under 5 µM WIN treatment in both intracellular or
extracellular fractions. β-actin bl t or Ponceau red staining wer reported s a loading control for
intracellular or extracellular protein levels, respectively. Representative blots of three independent
experiments and densitometry analysis histograms are depicted. (*) p < 0.05, (**) p < 0.01 compared
to the untreated sample at the same time point. N.S. not significant. (B) Effects of siSPARC on cell
migration in comparison with scramble control (siScr). Pictures reported were taken at T36 after
wounding (magnification 200×). The average distances between cells at the edges of the gaps in the
wound healing assay were esti ated through I ageJ software. On the right panel, a graph of the mean
percentage area healed at T36 post-wounding is shown. (**) p < 0.01 compared to untreated cells at the
same time point. N.S. not significant.
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2.4. WIN Induces the Upregulation of miR-29b1 which Plays a Role in Cell Migration
To explore the mechanism by which WIN prevents cell migration, we focused on miR-29b1, which
is considered a mediator of the migratory ability of cancer cells [28,30]. Real-time PCR experiments
showed that WIN induces an upregulation of this miRNA of about 700-fold compared with untreated
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MG63 cells (Figure 7A). To investigate the role of this miRNA on cell migration, we transfected MG63
cells with a vector carrying miR-29b1 and selected a stable line overexpressing this miRNA (Figure 7B).
Then, we analysed the motility of these cells by means of wound healing assay. Similar to WIN-treated
cells, after 36 h, only a small percentage of transfected cells migrated into the wound, whereas mock
transfected cells showed a migratory activity of about 80% with respect to that observed in untreated
cells (Figure 7C). Moreover, miR-29b1 transfected cells showed a reduced extracellular activity of
matrix metalloprotease 9 and 2 (MMP9 and MMP2) (Figure 7D), mimicking the WIN effect. In addition,
also the intracellular levels of both MMPs were reduced in miRNA transfected cells (not shown).
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transfected with mock alone. Pictures were taken at the indicated time points after wounding
(magnification 200×). The average distances between cells at the edges of the gaps in the wound
healing assay was estimated through ImageJ software. On the right of the picture, a graph of the
mean percentage area healed at T8, T24 and T36 post-wounding is shown. (**) p < 0.01 and (***)
p < 0.001 compared to the untreated cells at the same time point. (D) Gelatin zymography of MMP2
and MMP9 in miR-29b1-transfected cells versus mock transfected cells. Arrows indicate the relative
bands at 72 kDa (MMP2) and 92 kDa (MMP9). Volumes containing equal amount of proteins were
loaded. Densitometry values are averaged from three independent experiments. (***) p < 0.001. (E)
Western blotting analysis of SPARC level in miR-29b1 overexpressing cells. The results were obtained
by immunoblotting employing a specific SPARC antibody as reported in Section 4. β-actin blot was
included as a loading control. Densitometry values are averaged from four independent experiments
normalized to β-actin. N.S. not significant.
Since miR-29b1 is considered a putative post-transcriptional regulator of SPARC expression [30],
we evaluated the level of SPARC in miR-29b1 overexpressing cells. As shown in Figure 7E, the
overexpression of miR-29b1 did not cause any change in the level of SPARC, so we concluded that, in
our experimental model, SPARC is not a direct target of miR-29b1, as predicted by in silico analysis.
3. Discussion
Cell migration represents an essential step during tumour progression, and therefore inhibitors
of this process can be considered as potential antimetastatic drugs. On the basis of our previous
results on apoptosis induction by WIN55,212-2 in osteosarcoma cells [19,20], in the current study,
we show the ability of this compound to block osteosarcoma cell migration and we characterize the
mechanism involved. Specifically, we demonstrate here that WIN markedly reduced the migratory
ability of osteosarcoma MG63 cells, and this effect was accompanied by a dramatic reduction in
the extracellular activity and intracellular levels of MMP2 and MMP9 metalloproteases. Although
conflicting data are present in the literature regarding the expression levels of metalloproteases in
osteosarcoma cells [31,32], we found that, in our serum-free conditions, both the intracellular levels and
extracellular activity of MMP9 were higher than those of MMP2. Fragmentary data in the literature
demonstrate that WIN can inhibit the epithelial mesenchymal transition and migration in different
cancer cell models [33,34] In an attempt to clarify the mechanism of the anti-migratory effect of WIN in
osteosarcoma cells, our study specifically focuses on a possible involvement of the matricellular protein
SPARC and a hypothetical role exerted by miR-29b1. SPARC is often considered as an ambiguous gene
product because it plays opposite roles in extracellular matrix remodelling and carcinogenesis [24].
Despite the fact that we have previously demonstrated a crucial role exerted by intracellular SPARC
in WIN-induced apoptosis in osteosarcoma cells, in this paper, we demonstrate that SPARC is not
involved in the anti-migratory effect of WIN. Indeed, although WIN upregulated intracellular SPARC,
it markedly prevented its release and restrained the protein inside the cells by inhibiting the canonical
secretory pathway. This conclusion is based on the observation that, in our model, WIN mimicked the
effects of BAPTA-AM and thapsigargin, two selective inhibitors of the secretory pathway. We also
demonstrate that WIN increased the production of extracellular vesicles, in which SPARC was not
present. Moreover, as a confirmation that the anti-migratory effect of WIN was independent of
SPARC, the knockdown of this factor by RNA interference did not influence the migratory ability of
osteosarcoma cells either in the presence or absence of WIN.
In our opinion, an interesting point in this study is the evidence that WIN induced a marked
increase in the amount of secreted EVs and that EVs isolated from WIN-treated cells exerted a significant
anti-migratory effect in untreated cultures. Ongoing studies in our laboratory attempt to characterize
by proteomic analysis the content of WIN-induced EVs and this will shed light on the factors involved
in WIN-mediated intercellular communication.
Osteosarcoma cells are characterized by the downregulation of miR-29 family members which
exert an anti-proliferative and pro-apoptotic role in this cancer and sensitize the cells to the effects of
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chemotherapeutic agents [35]. Interestingly, we demonstrate that WIN induced a dramatic increase in
the level of miR-29b1, and that the stable overexpression of this miRNA produced a decrease in cell
migration and a reduction of MMP2 and MMP9 activity similar to those observed in WIN-treated cells.
This represents the first evidence that miR-29b1 is able to induce the downregulation of both MMP2
and MMP9. Figure 8 shows a schematic representation of the WIN-induced mechanism responsible for
its anti-migratory effect in osteosarcoma MG63 cells. The preventive role of miR-29b1 on cell migration
is in accordance with data recently reported by Zhu et al. [36] which demonstrate a role of miR-29 in
the regulation of osteosarcoma cell proliferation and migration in connection with CDK6. Our current
study aims to verify the presence of miR-29b1 in WIN-induced EVs and discriminate the vesicle types.
Moreover, another intriguing aspect concerns the relationship between cannabinoid effects and the
specific receptors (CB1-R and/or CB2-R) expressed in the different cancer models [37]. In this regard,
we consider it relevant to characterize the cannabinoid receptor in osteosarcoma cells that is responsible
for the anti-migratory effect of WIN.
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In conclusion, considering that the five-year survival rate in metastatic osteosarcoma is about
15–30% and that no specific drug has been found to date, the understanding of molecular mechanisms
that regulate osteosarcoma migration and the potential role exerted by the cannabinoid WIN may have
important implications for more specific osteosarcoma treatment.
4. Materials and Methods
4.1. Reagents
R-[2,3-Dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naph
thalenyl methanone mesylate (WIN55,212-2) was purchased from Sigma, (Sigma Aldrich, Milan,
Italy). Stock solutions were prepared in DMSO and opportunely diluted in culture medium. The
final concentration of DMSO never exceeded 0.04%, which is a concentration that was experimentally
determined to have no discernible effect. All the experiments were carried out using vehicle alone as a
control. Antibody against SPARC was purchased from Takara (Takara Bio Clontech, Mountain View,
CA, USA), anti β-actin from Sigma (Sigma Aldrich, Italy) and anti-MMP2 and MMP9 from Santa Cruz
Biotechnology (Santa. Cruz, CA, USA).
4.2. Cell Cultures
Human osteosarcoma MG63 cells were acquired from Interlab Cell Line Collection (ICLC; Genoa,
Italy). Cells were cultured at 37 ◦C in Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% (v/v) heat-inactivated foetal bovine serum (FBS), 2.0 mM L-gluta ine, and antibiotic
anti ycotic solution (100 U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin B;
Sigma, Milan, Italy) in a humidified at osphere co taining 5% CO2. For the experiments, cells were
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seeded in 96 or six-well plates, and after 24 h, culture medium was replaced with fresh serum-free
DMEM before cannabinoid treatment.
4.3. Wound Healing Assay
Changes of migration and motility of cancer cells were examined using a wound-healing assay [38].
Cells (106) were seeded in six-well dishes to achieve approximately 90% confluence. Using a sterile
200 µL pipette tip, a straight scratch simulating a wound in a monolayer was made. After scratching,
wells were gently washed with medium to remove the detached cells, and fresh serum-free DMEM
medium was added. MG63 cells were treated with the vehicle (untreated cells), 5 µM WIN or 50 µg/mL
EVs. In other experiments, before WIN treatment, the medium was replaced with serum-free medium
from highly confluent untreated cultures. The plates were then incubated at 37 ◦C, and the speed of
cell movement across the gap was observed. Digital documentation at the same position was made
after scratching at time zero (T0) and after 8, 24 and 36 h and captured by a computer-imaging system
(Leica DC300F camera and Adobe Photoshop for image analysis). The effects on cell migration and
motility were estimated by using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
The area of the remaining wound was determined as the ratio between the residual area at a given
time point and the original wound area (T0) × 100.
4.4. Gelatin Zymography
The enzymatic activity of MMP2 and MMP9 was measured by gelatin zymography in 10%
SDS-polyacrylamide separating gels in the presence of gelatin. Cells were treated with 5 µM WIN for
24 h, and the conditioned media from untreated or WIN-treated cells were collected and centrifuged
(2000× g for 5 min) to remove cells and cell debris. The amount of total protein in the supernatants
was assessed by the Bradford assay (Bio-Rad, Segrate, Milan, Italy) according to the manufacturer’s
protocol. Supernatants were incubated with an adequate volume of SDS sample loading buffer without
β-mercaptoethanol and separated by electrophoresis. Following electrophoresis, gels were rinsed with
enzyme renaturing buffer containing 2.5% Triton X-100 in 50 mM Tris-HCl (pH 7.5) for 60 min at room
temperature. Subsequently, gels were incubated in developing buffer (0.15 M NaCl, 10 mM CaCl2, in
50 mM Tris-HCl, pH 7.5) for 24 h at 37 ◦C, stained with Coomassie brilliant blue R-250 solution for 2 h
and destained in methanol, acetic acid and water (50:10:40) solution until clear bands of MMPs activity
were visible on the dark blue background. Digestive activity of MMPs was confirmed by the presence
of two bands on zymograms, slower migrating MMP9 and faster migrating MMP2 in comparison with
a standard of molecular weight.
4.5. Western Blot Analysis
To evaluate the extracellular protein content, conditioned culture media were dialyzed using 5000
cut off dialysis tubing and concentrated by lyophilization. Samples reconstituted with water were
separated by electrophoresis under reducing conditions. For the evaluation of intracellular proteins,
extracts were prepared as previously reported [39,40]. Ponceau red staining (for extracellular proteins),
AChEase activity (for SPARC in EVs) or β-actin blots (for intracellular proteins) were reported as
loading control. The blots were developed using the enhanced chemiluminescence (ECL) labeling
system or alkaline phosphatase colorimetric system. Optical densities of the bands were analysed
with Quantity One Imaging software from Bio-Rad Laboratories. The results shown in the figures are
representative of at least three independent experiments with similar results.
4.6. Isolation and Quantification of Extracellular Vesicles from Culture Media
Extracellular vesicles (EVs) were purified from medium as previously described [41]. Briefly,
conditioned media by subconfluent cells were centrifuged at 2000× g for 10 min and at 4000× g for
15 min to remove cells and large debris. The supernatant was ultracentrifuged in a 70-Ti rotor (Beckman
Coulter, Brea, CA, USA), at 105,000× g for 90 min at 4 ◦C, and pelleted vesicles were resuspended in
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filtered PBS. The protein content of isolated EVs was determined using the Bradford method (Bio-Rad,
Segrate, Milan, Italy) with bovine serum albumin as standard.
The number of obtained EVs was determined by flow cytometry with a FACSCanto instrument
(BD Biosciences, Erembodegem, Belgium) as previously described. Briefly, 1 µL of EVs was diluted in
a fixed volume of 200 µL of filtered PBS (0.1 µM filter); all samples were analysed by FACS for 30 s at
medium flow rate. The event number corresponds to the number of EVs present in a specific volume
of sample [42].
EVs release was also quantified by measuring the activity of acetylcholinesterase (AchEase) by
Ellman assay [43]. Briefly, EVs (5 µL) were suspended in filtered PBS (95 µL) and incubated with
1.25 mM acetylthiocholine chloride (Sigma, Milan, Italy) and 0.1 mM 5,5′-dithio-bis(2-nitrobenzoic
acid) (Sigma, Milan, Italy). PBS was then added to a final volume of 1 mL, and the change in absorbance
at 412 nm was monitored every 5 min for 20 min.
4.7. Gene Silencing Using siRNA
Small interfering RNAs (siRNAs) against SPARC (5’-AACAAGACCUUCGACUCUUCC-3’)
(siSPARC) and scrambled siRNA (siScr), as a negative non-silencing control, were purchased from
Dharmacon RNA Technologies (Chicago, IL, USA). For the experiments, cells (105) were seeded in
six-well plates and cultured in antibiotic-free DMEM supplemented with 2.0 mM L-glutamine, until
50% confluence. Then, cells were transfected with 30 nM siSPARC or siScr in the presence of 5 µL
Metafectene Pro (Biontex Laboratories GmbH, Martinsried/Planegg, Germany) in a final volume of
1 mL serum-free medium. The reaction was stopped after 6 h replacing the culture medium with fresh
10% FBS DMEM. After 48 h from transfection, silenced cells were treated with WIN for other 24 h.
4.8. Real-Time PCR for miR-29b1 Expression
RNA was extracted by Direct Zol RNA Mini-Prep (Zymo research, Freiburg, Germany). A DNase
I treatment step was included. Twenty nanograms of total RNA was reverse transcripted in a final
volume of 10 µL by using miRCURY LNATM Universal RT microRNA PCR kit (Exiqon, Mi, Italy)
according to the manufacturer’s instructions. The resulting cDNAs were used for quantitative analysis
by real-time PCR (qPCR) using miR-29b1 LNA™ primers (204261; Exiqon) and SYBR Green Master Mix
(Exiqon). Reactions were performed in 96-well plates according to manufacturer’s instructions, using
Bio-Rad instrument, as previously reported [44]. qPCR was performed in triplicate and repeated for
confirmation. U6 small nuclear RNA was used as internal control for miRNA detection. Data processing
and statistical analysis were performed by using IQ5 cycler software. The relative quantification in
gene expression was determined using the 2−∆∆Ct method.
4.9. Stable Transfection of MG63 Cells with miR-29b1 Plasmid Vector
For the stable transfection of MG63 cells expressing miR-29b1, a specific plasmid construct,
prepared as reported in [44], was employed. Before stable transfection, cells were seeded in six-well
plates until they reached 90% confluence and then transfected with 4 µg of miR-29b1 expression vector
or empty vector (mock) encoding the green fluorescent protein (GFP), by using Lipofectamine 2000
(InvitrogenTM, Monza, Italy) according to manufacturer’s instructions. The efficiency of transfection
was evaluated by monitoring the ratio of transfected cells showing GFP fluorescence in relation to all
cells. Two days after transfections, the cells were transferred in 100 mm dishes in selective medium
containing 1 µg/mL Puromycin. The medium was replaced every 3–4 days. A plate of non-transfected
cells was used as a control for the selection.
4.10. Statistical Analysis
Data, reported as means ± SD from at least three independent experiments, were analysed using
the Student’s t-test. Differences were considered significant at p < 0.05.
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